EINDHOVEN, the Netherlands, May 15, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V.
(Euronext: ONWD), the medical technology company creating innovative spinal cord
stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that it will host a webcast to discuss its Q1 2024 business highlights.
The webcast will be held on May 23, 2024, at 2:30PM CET / 08:30AM ET. It will be
hosted by CEO Dave Marver who will discuss highlights from Q1 2024 and provide a
business update.
To join the webcast via Zoom, please register using this link (https://onwd.zoom.us/webinar/register/WN_XauQicu-QLCMZJISJPAJlg).
Participants may also join by phone:
+32 2 290 9360 (Belgium)
+49 69 3807 9884 (Germany)
+31 20 794 0854 (Netherlands)
+41 22 591 0156 (Switzerland)
+44 203 481 5240 (United Kingdom)
+1 346 248 7799 (US)
Additional telephone numbers available
Meeting ID: 879 5741 2479
A recording of the webcast will be available on the Company's website following the live event.
To learn more about ONWARD Medical's commitment to partnering with the SCI Community to develop innovative solutions for restoring movement, function, and independence after spinal cord injury, please visit ONWD.com.
*All ONWARD(®) Medical devices and therapies, including but not limited to ARC-
IM(®), ARC-EX(®), ARC-BCI((TM)), and ARC Therapy((TM)), alone or in combination with a
brain-computer interface (BCI), are investigational and not available for
commercial use.
About ONWARD Medical
ONWARD(®) Medical is a medical technology company creating therapies to restore
movement, function, and independence in people with spinal cord injury (SCI) and
movement disabilities. Building on more than a decade of scientific discovery,
preclinical, and clinical research conducted at leading hospitals,
rehabilitation clinics, and neuroscience laboratories, the Company has developed
ARC Therapy((TM)), which has been awarded ten Breakthrough Device Designations from
the US Food and Drug Administration (FDA).
ONWARD ARC Therapy, which can be delivered by external ARC-EX(®) or implantable
ARC-IM(®) systems, is designed to deliver targeted, programmed spinal cord
stimulation. Positive results were presented in 2023 from the Company's pivotal
study, called Up-LIFT, evaluating the ability for transcutaneous ARC Therapy to
improve upper extremity strength and function. The Company has submitted a
regulatory application to the FDA for clearance of the ARC-EX System in the US
and is preparing for regulatory submission in Europe. In parallel, the Company
is conducting studies with its implantable ARC-IM Therapy, which demonstrated
positive interim clinical outcomes for improved blood pressure regulation
following SCI. Other ongoing studies include use of ARC-IM Therapy to address
mobility after SCI and gait challenges in Parkinson's disease as well as using
the ARC-BCI platform to restore thought-driven movement of both upper and lower
limbs after SCI.
Headquartered in Eindhoven, the Netherlands, ONWARD Medical has a Science and
Engineering Center in Lausanne, Switzerland and a US office in Boston,
Massachusetts. The Company is listed on Euronext Brussels and Amsterdam (ticker:
ONWD).
For more information, visit ONWD.com, and connect with us on LinkedIn and
YouTube.
For Media Inquiries:
Aditi Roy, VP Communications
media@onwd.com (mailto:media@onwd.com)
For Investor Inquiries:
Amori Fraser, Finance Director
investors@onwd.com (mailto:investors@onwd.com)
Disclaimer
Certain statements, beliefs, and opinions in this press release are forward-
looking, which reflect the Company's or, as appropriate, the Company directors'
current expectations and projections about future events. By their nature,
forward-looking statements involve several risks, uncertainties, and assumptions
that could cause actual results or events to differ materially from those
expressed or implied by the forward-looking statements. These risks,
uncertainties, and assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of factors
including, but not limited to, changes in demand, competition, and technology,
can cause actual events, performance, or results to differ significantly from
any anticipated development. Forward-looking statements contained in this press
release regarding past trends or activities should not be taken as a
representation that such trends or activities will continue in the future. As a
result, the Company expressly disclaims any obligation or undertaking to release
any update or revisions to any forward-looking statements in this press release
as a result of any change in expectations or any change in events, conditions,
assumptions, or circumstances on which these forward-looking statements are
based. Neither the Company nor its advisers or representatives nor any of its
subsidiary undertakings or any such person's officers or employees guarantees
that the assumptions underlying such forward-looking statements are free from
errors nor does either accept any responsibility for the future accuracy of the
forward-looking statements contained in this press release or the actual
occurrence of the forecasted developments. You should not place undue reliance
on forward-looking statements, which speak only as of the date of this press
release. All ONWARD Medical devices and therapies referenced here, including but
not limited to ARC-IM(®), ARC-EX(®), ARC-BCI(TM) and ARC Therapy(TM), are
investigational and not available for commercial use.
Â